Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 47 entries
Sorted by: Best Match Show Resources per page
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Clinical sarcoma research

Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P.
PMID: 27651889
Clin Sarcoma Res. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016.

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used...

Cite
Gaston CL, Grimer RJ, Parry M, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016;6(1):15doi: 10.1186/s13569-016-0056-0.
Gaston, C. L., Grimer, R. J., Parry, M., Stacchiotti, S., Dei Tos, A. P., Gelderblom, H., Ferrari, S., Baldi, G. G., Jones, R. L., Chawla, S., Casali, P., LeCesne, A., Blay, J. Y., Dijkstra, S. P., Thomas, D. M., & Rutkowski, P. (2016). Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical sarcoma research, 6(1), 15. https://doi.org/10.1186/s13569-016-0056-0
Gaston, Czar Louie, et al. "Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone." Clinical sarcoma research vol. 6,1 (2016): 15. doi: https://doi.org/10.1186/s13569-016-0056-0
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016. PMID: 27651889; PMCID: PMC5022265.
Copy Download .nbib Format: NLM
Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature.

Frontiers in oncology

Giannini L, Incandela F, Fiore M, Gronchi A, Stacchiotti S, Sangalli C, Piazza C.
PMID: 30386739
Front Oncol. 2018 Oct 17;8:449. doi: 10.3389/fonc.2018.00449. eCollection 2018.

In the last decades, radiotherapy (RT) has become one of the cornerstones in the treatment of head and neck (HN) malignancies and has paralleled an increase in long-term patient survival. This lead to a concomitant increase in the incidence...

Cite
Giannini L, Incandela F, Fiore M, et al. Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. Front Oncol. 2018;8:449doi: 10.3389/fonc.2018.00449.
Giannini, L., Incandela, F., Fiore, M., Gronchi, A., Stacchiotti, S., Sangalli, C., & Piazza, C. (2018). Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. Frontiers in oncology, 8449. https://doi.org/10.3389/fonc.2018.00449
Giannini, Lorenzo, et al. "Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature." Frontiers in oncology vol. 8 (2018): 449. doi: https://doi.org/10.3389/fonc.2018.00449
Giannini L, Incandela F, Fiore M, Gronchi A, Stacchiotti S, Sangalli C, Piazza C. Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. Front Oncol. 2018 Oct 17;8:449. doi: 10.3389/fonc.2018.00449. eCollection 2018. PMID: 30386739; PMCID: PMC6199463.
Copy Download .nbib Format: NLM
The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.

Cancer communications (London, England)

Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S.
PMID: 30486883
Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3.

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, and poorly investigated simple sarcoma with a low frequency of genetic deregulation other than an Ewing sarcoma RNA binding protein 1 (EWSR1)-Wilm's tumor suppressor (WT1) translocation. We used...

Cite
Devecchi A, De Cecco L, Dugo M, et al. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun (Lond). 2018;38(1):70doi: 10.1186/s40880-018-0339-3.
Devecchi, A., De Cecco, L., Dugo, M., Penso, D., Dagrada, G., Brich, S., Stacchiotti, S., Sensi, M., Canevari, S., & Pilotti, S. (2018). The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer communications (London, England), 38(1), 70. https://doi.org/10.1186/s40880-018-0339-3
Devecchi, Andrea, et al. "The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response." Cancer communications (London, England) vol. 38,1 (2018): 70. doi: https://doi.org/10.1186/s40880-018-0339-3
Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3. PMID: 30486883; PMCID: PMC6260689.
Copy Download .nbib Format: NLM
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Clinical sarcoma research

Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, Casali PG, Picci P.
PMID: 28261443
Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017.

BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number...

Cite
Marchesi E, Cagnazzo C, Quattrini I, et al. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res. 2017;7:4doi: 10.1186/s13569-017-0068-4.
Marchesi, E., Cagnazzo, C., Quattrini, I., Leopardi, M. P., Villa, C., Grignani, G., D'Ambrosio, L., Stacchiotti, S., Casali, P. G., & Picci, P. (2017). How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clinical sarcoma research, 74. https://doi.org/10.1186/s13569-017-0068-4
Marchesi, Emanuela, et al. "How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience." Clinical sarcoma research vol. 7 (2017): 4. doi: https://doi.org/10.1186/s13569-017-0068-4
Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, Casali PG, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017. PMID: 28261443; PMCID: PMC5329913.
Copy Download .nbib Format: NLM
Peritonitis due to Empedobacter brevis in a patient on peritoneal dialysis: An emerging pathogen.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

D'Ostilio A, Stacchiotti L, Perilli A, Di Bari M, Amoroso L.
PMID: 34272824
Ther Apher Dial. 2021 Jul 17; doi: 10.1111/1744-9987.13709. Epub 2021 Jul 17.

No abstract available.

Cite
D'Ostilio A, Stacchiotti L, Perilli A, et al. Peritonitis due to Empedobacter brevis in a patient on peritoneal dialysis: An emerging pathogen. Ther Apher Dial. 2021;doi: 10.1111/1744-9987.13709.
D'Ostilio, A., Stacchiotti, L., Perilli, A., Di Bari, M., & Amoroso, L. (2021). Peritonitis due to Empedobacter brevis in a patient on peritoneal dialysis: An emerging pathogen. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, . https://doi.org/10.1111/1744-9987.13709
D'Ostilio, Annamaria, et al. "Peritonitis due to Empedobacter brevis in a patient on peritoneal dialysis: An emerging pathogen." Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy vol. (2021). doi: https://doi.org/10.1111/1744-9987.13709
D'Ostilio A, Stacchiotti L, Perilli A, Di Bari M, Amoroso L. Peritonitis due to Empedobacter brevis in a patient on peritoneal dialysis: An emerging pathogen. Ther Apher Dial. 2021 Jul 17; doi: 10.1111/1744-9987.13709. Epub 2021 Jul 17. PMID: 34272824.
Copy Download .nbib Format: NLM
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.

CPT: pharmacometrics & systems pharmacology

Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap WD, Gelderblom H, Wagner AJ, Healey JH, Greenberg J, Shuster D, Stacchiotti S.
PMID: 34585528
CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432. doi: 10.1002/psp4.12712. Epub 2021 Oct 14.

This analysis was conducted to assess exposure-response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluation Criteria in Solid Tumors version 1.1...

Cite
Yin O, Zahir H, French J, et al. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT Pharmacometrics Syst Pharmacol. 2021;10(11):1422-1432doi: 10.1002/psp4.12712.
Yin, O., Zahir, H., French, J., Polhamus, D., Wang, X., van de Sande, M., Tap, W. D., Gelderblom, H., Wagner, A. J., Healey, J. H., Greenberg, J., Shuster, D., & Stacchiotti, S. (2021). Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: pharmacometrics & systems pharmacology, 10(11), 1422-1432. https://doi.org/10.1002/psp4.12712
Yin, Ophelia, et al. "Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor." CPT: pharmacometrics & systems pharmacology vol. 10,11 (2021): 1422-1432. doi: https://doi.org/10.1002/psp4.12712
Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap WD, Gelderblom H, Wagner AJ, Healey JH, Greenberg J, Shuster D, Stacchiotti S. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432. doi: 10.1002/psp4.12712. Epub 2021 Oct 14. PMID: 34585528; PMCID: PMC8592513.
Copy Download .nbib Format: NLM
SELNET clinical practice guidelines for soft tissue sarcoma and GIST.

Cancer treatment reviews

Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J.
PMID: 34798363
Cancer Treat Rev. 2021 Nov 14;102:102312. doi: 10.1016/j.ctrv.2021.102312. Epub 2021 Nov 14.

No abstract available.

Cite
Blay JY, Hindi N, Bollard J, et al. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 2021;102:102312doi: 10.1016/j.ctrv.2021.102312.
Blay, J. Y., Hindi, N., Bollard, J., Aguiar, S., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Caro-Sánchez, C. H. S., Carvajal, B., Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, V., Chacón, M., Clara, M., Collini, P., Correa Genoroso, R., Costa, F. D., Cuellar, M., Dei Tos, A. P., Dominguez Malagon, H. R., Donati, D., Dufresne, A., Eriksson, M., Farias-Loza, M., Fernandez, P., Frezza, A. M., Frisoni, T., Garcia-Ortega, D. Y., Gelderblom, H., Gouin, F., Gómez-Mateo, M. C., Gronchi, A., Haro, J., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes David, B. B., Lopez-Pousa, A., Lutter, G., Martinez-Said, H., Martinez-Tlahuel, J., Mello, C. A., Morales Pérez, J. M., Moura David, S., Nascimento, A. G., Ortiz-Cruz, E. J., Palmerini, E., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Salas, R., Santos, T. T. G., Scotlandi, K., Soule, T., Stacchiotti, S., Valverde, C., Waisberg, F., Zamora Estrada, E., & Martin-Broto, J. (2021). SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer treatment reviews, 102102312. https://doi.org/10.1016/j.ctrv.2021.102312
Blay, J Y, et al. "SELNET clinical practice guidelines for soft tissue sarcoma and GIST." Cancer treatment reviews vol. 102 (2021): 102312. doi: https://doi.org/10.1016/j.ctrv.2021.102312
Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 2021 Nov 14;102:102312. doi: 10.1016/j.ctrv.2021.102312. Epub 2021 Nov 14. PMID: 34798363.
Copy Download .nbib Format: NLM
SELNET clinical practice guidelines for soft tissue sarcoma and GIST.

Cancer treatment reviews

Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J.
PMID: 34798363
Cancer Treat Rev. 2021 Nov 14;102:102312. doi: 10.1016/j.ctrv.2021.102312. Epub 2021 Nov 14.

No abstract available.

Cite
Blay JY, Hindi N, Bollard J, et al. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 2021;102:102312doi: 10.1016/j.ctrv.2021.102312.
Blay, J. Y., Hindi, N., Bollard, J., Aguiar, S., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Caro-Sánchez, C. H. S., Carvajal, B., Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, V., Chacón, M., Clara, M., Collini, P., Correa Genoroso, R., Costa, F. D., Cuellar, M., Dei Tos, A. P., Dominguez Malagon, H. R., Donati, D., Dufresne, A., Eriksson, M., Farias-Loza, M., Fernandez, P., Frezza, A. M., Frisoni, T., Garcia-Ortega, D. Y., Gelderblom, H., Gouin, F., Gómez-Mateo, M. C., Gronchi, A., Haro, J., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes David, B. B., Lopez-Pousa, A., Lutter, G., Martinez-Said, H., Martinez-Tlahuel, J., Mello, C. A., Morales Pérez, J. M., Moura David, S., Nascimento, A. G., Ortiz-Cruz, E. J., Palmerini, E., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Salas, R., Santos, T. T. G., Scotlandi, K., Soule, T., Stacchiotti, S., Valverde, C., Waisberg, F., Zamora Estrada, E., & Martin-Broto, J. (2021). SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer treatment reviews, 102102312. https://doi.org/10.1016/j.ctrv.2021.102312
Blay, J Y, et al. "SELNET clinical practice guidelines for soft tissue sarcoma and GIST." Cancer treatment reviews vol. 102 (2021): 102312. doi: https://doi.org/10.1016/j.ctrv.2021.102312
Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 2021 Nov 14;102:102312. doi: 10.1016/j.ctrv.2021.102312. Epub 2021 Nov 14. PMID: 34798363.
Copy Download .nbib Format: NLM
Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.

Cancer

Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, Morosi C, Barisella M, Frezza AM, Provenzano S, Simeone N, Picozzi F, Mariani L, Casali PG, Stacchiotti S.
PMID: 35026050
Cancer. 2022 Jan 13; doi: 10.1002/cncr.34083. Epub 2022 Jan 13.

BACKGROUND: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network.METHODS: Adult patients with a diagnosis of...

Cite
Baldi GG, Lo Vullo S, Grignani G, et al. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. Cancer. 2022;doi: 10.1002/cncr.34083.
Baldi, G. G., Lo Vullo, S., Grignani, G., Vincenzi, B., Badalamenti, G., Mastore, M., Buonomenna, C., Morosi, C., Barisella, M., Frezza, A. M., Provenzano, S., Simeone, N., Picozzi, F., Mariani, L., Casali, P. G., & Stacchiotti, S. (2022). Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. Cancer, . https://doi.org/10.1002/cncr.34083
Baldi, Giacomo G, et al. "Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network." Cancer vol. (2022). doi: https://doi.org/10.1002/cncr.34083
Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, Morosi C, Barisella M, Frezza AM, Provenzano S, Simeone N, Picozzi F, Mariani L, Casali PG, Stacchiotti S. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. Cancer. 2022 Jan 13; doi: 10.1002/cncr.34083. Epub 2022 Jan 13. PMID: 35026050.
Copy Download .nbib Format: NLM
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.

Molecular cancer therapeutics

Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A.
PMID: 34552008
Mol Cancer Ther. 2021 Dec;20(12):2539-2552. doi: 10.1158/1535-7163.MCT-21-0315. Epub 2021 Sep 22.

MRP-1 is implicated in multidrug resistance and was described as prognostic in high-risk patients with soft-tissue sarcoma (STS) in a previous study. The current research aimed to validate MRP-1 prognostic/predictive value in localized sarcomas treated with anthracyclines plus ifosfamide...

Cite
Martin-Broto J, Lopez-Alvarez M, Moura DS, et al. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Mol Cancer Ther. 2021;20(12):2539-2552doi: 10.1158/1535-7163.MCT-21-0315.
Martin-Broto, J., Lopez-Alvarez, M., Moura, D. S., Ramos, R., Collini, P., Romagosa, C., Bagué, S., Renne, S. L., Barisella, M., Velasco, V., Coindre, J. M., Lopez-Lopez, D., Dopazo, J., Gambarotti, M., Braglia, L., Merlo, D. F., Palmerini, E., Stacchiotti, S., Quagliuolo, V. L., Lopez-Pousa, A., Grignani, G., Blay, J. Y., Brunello, A., Gutierrez, A., Valverde, C., Hindi, N., Dei Tos, A. P., Picci, P., Casali, P. G., & Gronchi, A. (2021). Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Molecular cancer therapeutics, 20(12), 2539-2552. https://doi.org/10.1158/1535-7163.MCT-21-0315
Martin-Broto, Javier, et al. "Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial." Molecular cancer therapeutics vol. 20,12 (2021): 2539-2552. doi: https://doi.org/10.1158/1535-7163.MCT-21-0315
Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Mol Cancer Ther. 2021 Dec;20(12):2539-2552. doi: 10.1158/1535-7163.MCT-21-0315. Epub 2021 Sep 22. PMID: 34552008.
Copy Download .nbib Format: NLM
Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.

EClinicalMedicine

Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, Stacchiotti S, Pèchoux CL, Smith MJ, Fiore M, Tos APD, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, Casali PG, Wunder JS, Gronchi A.
PMID: 31891146
EClinicalMedicine. 2019 Nov 22;17:100215. doi: 10.1016/j.eclinm.2019.11.008. eCollection 2019 Dec.

BACKGROUND: Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and externally validate a dynamic prognostic nomogram...

Cite
Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. EClinicalMedicine. 2019;17:100215doi: 10.1016/j.eclinm.2019.11.008.
Callegaro, D., Miceli, R., Bonvalot, S., Ferguson, P. C., Strauss, D. C., van Praag, V. V. M., Levy, A., Griffin, A. M., Hayes, A. J., Stacchiotti, S., Pèchoux, C. L., Smith, M. J., Fiore, M., Tos, A. P. D., Smith, H. G., Catton, C., Szkandera, J., Leithner, A., van de Sande, M. A. J., Casali, P. G., Wunder, J. S., & Gronchi, A. (2019). Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. EClinicalMedicine, 17100215. https://doi.org/10.1016/j.eclinm.2019.11.008
Callegaro, Dario, et al. "Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors." EClinicalMedicine vol. 17 (2019): 100215. doi: https://doi.org/10.1016/j.eclinm.2019.11.008
Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, Stacchiotti S, Pèchoux CL, Smith MJ, Fiore M, Tos APD, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, Casali PG, Wunder JS, Gronchi A. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. EClinicalMedicine. 2019 Nov 22;17:100215. doi: 10.1016/j.eclinm.2019.11.008. eCollection 2019 Dec. PMID: 31891146; PMCID: PMC6933187.
Copy Download .nbib Format: NLM
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY.
PMID: 30188977
Ann Oncol. 2018 Oct 01;29:iv267. doi: 10.1093/annonc/mdy320.

No abstract available.

Cite
Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv267doi: 10.1093/annonc/mdy320.
Casali, P. G., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., Buonadonna, A., De Álava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A. M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R. L., Hassan, B., Hohenberger, P., Issels, R., Joensuu, H., Jones, R. L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krákorová, D. A., Le Cesne, A., Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M. A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A. L., Reichardt, P., Robinson, M. H., Rutkowski, P., Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., van der Graaf, W. T. A., Whelan, J., Wardelmann, E., Zaikova, O., Blay, J. Y. (2018). Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 29iv267. https://doi.org/10.1093/annonc/mdy320
Casali, P G, et al. "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 (2018): iv267. doi: https://doi.org/10.1093/annonc/mdy320
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 01;29:iv267. doi: 10.1093/annonc/mdy320. PMID: 30188977.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 47 entries